Youil R, Su Q, Toner T J, Szymkowiak C, Kwan W-S, Rubin B, Petrukhin L, Kiseleva I, Shaw A R, DiStefano D
Merck & Co., Inc. 770 Sumneytown Pike, WP44L-206B, West Point, PA 19486, USA.
J Virol Methods. 2004 Sep 1;120(1):23-31. doi: 10.1016/j.jviromet.2004.03.011.
The choice of a cell line for the production of influenza vaccines is determined by how well the virus is able to replicate and how easily the cell line can be maintained. Madin-Darby canine kidney (MDCK) cells have long been known to successfully support influenza growth. Vero cells are also another well studied candidate cell line. In this work, we have compared these two cell lines for their ability to propagate type A and type B cold-adapted and wild type influenza viruses. The growth of these viruses has been measured as plaque forming units (via plaque assay) as well as viral particle formation (via a novel quantitative RT-PCR assay) to assess the suitability of these cell lines to support the development of live attenuated influenza vaccines. The novel qRT-PCR assay outlined in this work was demonstrated to be an efficient, sensitive and reproducible method for measuring wild type (wt) and cold-adapted (ca) influenza strains. Replicates of six per sample consistently showed an average variation around +/-10%. In this study we have also found qRT-PCR to be a useful method for differentiating between wt and ca influenza strains based on their differing growth characteristics at varying temperatures. This can subsequently be used to assess reassortants prepared from ca donor strains for the purposes of live viral vaccine development. For type A and B influenza viruses studied in this work, MDCK cells supported a more rapid viral growth (measured in terms of genome copies) compared with Vero cells. For the type A viruses studied here, the genome copies: infectious unit (genome copy, gc:infectious unit, iu) ratio was found to be more favorable for Vero cells compared with MDCK cells. For the type B viruses studied in this work, the gc:iu was equivalent in both cell lines tested. Ultimately, however, the use of any new cell line would need to be approved by regulatory agencies prior to its commercial application.
用于生产流感疫苗的细胞系选择取决于病毒的复制能力以及细胞系的维持难易程度。长期以来,人们都知道犬肾传代细胞(MDCK)能够成功支持流感病毒生长。非洲绿猴肾细胞(Vero)也是另一种经过充分研究的候选细胞系。在这项研究中,我们比较了这两种细胞系传播甲型和乙型冷适应及野生型流感病毒的能力。这些病毒的生长通过蚀斑形成单位(通过蚀斑试验)以及病毒颗粒形成(通过一种新型定量逆转录聚合酶链反应检测法)来衡量,以评估这些细胞系支持减毒活流感疫苗开发的适用性。这项研究中概述的新型定量逆转录聚合酶链反应检测法被证明是一种测量野生型(wt)和冷适应型(ca)流感毒株的高效、灵敏且可重复的方法。每个样本六个重复孔始终显示平均变异在±10%左右。在本研究中,我们还发现定量逆转录聚合酶链反应是一种基于野生型和冷适应型流感毒株在不同温度下不同生长特性来区分它们的有用方法。这随后可用于评估从冷适应供体毒株制备的重配体,以用于活病毒疫苗开发。对于本研究中所研究的甲型和乙型流感病毒,与Vero细胞相比,MDCK细胞支持病毒更快生长(以基因组拷贝数衡量)。对于此处研究的甲型病毒,发现与MDCK细胞相比,Vero细胞的基因组拷贝数:感染单位(基因组拷贝,gc:感染单位,iu)比值更有利。对于本研究中所研究的乙型病毒,在两种测试细胞系中gc:iu相当。然而,最终任何新细胞系在商业应用前都需要得到监管机构的批准。